Purchase this article with an account.
T. S. Prata, I. M. Tavares, P. A. A. Mello, C. Y. Tamura, R. Belfort, Jr.; Anterior Juxtascleral Depot of Anecortave Acetate: Intraocular Pressure Reduction in Different Types of Glaucoma. Invest. Ophthalmol. Vis. Sci. 2008;49(13):1205.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy and safety of anecortave acetate (AA) anterior juxtascleral depot (AJD) injection to reduce intraocular pressure (IOP) in glaucoma patients.
We conducted a prospective, non-randomized open-labeled clinical trial in 25 eyes of 25 uncontrolled glaucoma patients. All received a single AJD of AA (30 mg) in the selected eye under topical anesthesia. IOP was measured and adverse events were assessed at week 1, 1 month and 3 months.
Mean age was 60 (+/- 17) years. Most of the patients presented primary open angle glaucoma (8 - 32%) or uveitic / steroid induced glaucoma (9 - 36%). Regarding gonioscopy, 48% of the patients had an open angle, 12% < 90° of angle closure, and 40% >90° of angle closure. Mean IOP at baseline was 30.9 (+/- 9.2) mmHg and 53.5% of the patients had prior intraocular surgery. Mean IOP at the first three months were 20.9 (+/-7.5) mmHg, 21.5 (+/-7.6) mmHg and 19.1 (+/- 5.2) mmHg, respectively. Mean IOP reduction of 33.3%, 31.7% and 38.3% were observed at the first, second and third month, respectively. At month 3, angle closure glaucoma eyes had a mean IOP of 17.4 mmHg (reduction of 43.7%) while open angle glaucoma eyes had a mean IOP of 20.7 (reduction of 32.9%). A mild subconjunctival hemorrhage was observed in four cases. One eye developed a small and transient corneal dellen at the first week.
AA administered as an AJD presented a significant IOP reduction for at least three months with no clinically apparent serious adverse events in eyes with different types of glaucoma.
Clinical Trial: :
This PDF is available to Subscribers Only